FIGURE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

<p>Kaplan–Meier curves for the OS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 1.14 for those with HCV-UN (vs. HCV-d), 95% CI: 0.58–2.23 (<i>P</i> = 0.70).</p>

Duke Scholars

Author Andrew Benjamin Nixon Medicine, Medical Oncology